In today’s recent session, 0.76 million shares of the Athira Pharma Inc (NASDAQ:ATHA) have been traded, and its beta is 3.01. Most recently the company’s share price was $0.51, and it changed around $0.0 or 0.65% from the last close, which brings the market valuation of the company to $19.58M. ATHA at last check was trading at a discount to its 52-week high of $4.30, offering almost -743.14% off that amount. The share price’s 52-week low was $0.46, which indicates that the recent value has risen by an impressive 9.8% since then. We note from Athira Pharma Inc’s average daily trading volume that its 10-day average is 3.43 million shares, with the 3-month average coming to 650.29K.
Athira Pharma Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.67. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 3 recommended ATHA as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Athira Pharma Inc is expected to report earnings per share of -0.63 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Athira Pharma Inc (NASDAQ:ATHA) trade information
Instantly ATHA has been showing a green trend so far today with a performance of 0.65% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.5439 on recent trading dayincreased the stock’s daily price by 6.23%. The company’s shares are currently down -79.04% year-to-date, but still up 3.94% over the last five days. On the other hand, Athira Pharma Inc (NASDAQ:ATHA) is -82.62% down in the 30-day period. We can see from the shorts that 0.99 million shares have been sold at a short interest cover period of 8.18 day(s).
The consensus price target as assigned by Wall Street analysts is $18, which translates to bulls needing to increase their stock price by 97.17% from its current value. Analyst projections state that ATHA is forecast to be at a low of $3 and a high of $33.
Athira Pharma Inc (ATHA) estimates and forecasts
Athira Pharma Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -79.55 percent over the past six months and at a 18.12% annual growth rate that is well above the industry average of 17.40%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 27.60% in revenue this quarter, and will report an increase of 31.00% in the next quarter.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -81.69%.
ATHA Dividends
Athira Pharma Inc’s next quarterly earnings report is expected to be released on 2024-Nov-07.
Athira Pharma Inc (NASDAQ:ATHA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.17% of Athira Pharma Inc shares, and 63.76% of them are in the hands of institutional investors. The stock currently has a share float of 65.18%. Athira Pharma Inc stock is held by 82.0 institutions, with PERCEPTIVE ADVISORS LLC being the largest institutional investor. By 2024-06-30, it held 14.099% of the shares, which is about 5.4 million shares worth $14.32 million.
BAKER BROS. ADVISORS LP, with 8.2298% or 3.15 million shares worth $8.36 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
